NHS Introduces National Genetic Testing to Mitigate Donor Kidney Failure Risk

Introduction:

On 27 January 2025, NHS England announced the implementation of a national genetic testing program targeting potential kidney donors of Black African and Black Caribbean descent. The initiative focuses on detecting high-risk variants of the apolipoprotein L1 (APOL1) gene, which are associated with an increased risk of kidney disease post-donation. This proactive approach aims to improve donor safety and reduce health disparities within these communities.

Key Details:

APOL1 Gene and Kidney Disease Risk:
The APOL1 gene has variants that are more prevalent in individuals of Black African and Black Caribbean heritage. Research indicates that individuals possessing two high-risk variants of this gene have a significantly elevated risk of developing kidney disease. Approximately three out of five people with these high-risk variants may develop kidney disease after donating a kidney.

Testing Protocol and Implementation:
The NHS plans to conduct around 160 tests annually to identify potential donors carrying high-risk APOL1 variants. Individuals under 60 years old who are found to be at high risk will be advised against kidney donation to safeguard their health. This testing is now available nationwide, with samples analysed by the South West and South East Genomic Laboratory Hubs.

Broader Health Implications:
Beyond assessing donor suitability, this genetic testing initiative offers additional health benefits. Individuals identified as high-risk can receive regular monitoring, kidney check-ups, and guidance on lifestyle and dietary modifications to mitigate their risk of developing kidney disease in the future. This approach not only enhances donor safety but also contributes to reducing healthcare inequalities among Black African and Black Caribbean populations, who are statistically more susceptible to kidney disease compared to individuals of White heritage.

Implications for Clinical Practice:

Healthcare professionals involved in kidney transplantation should be aware of this new genetic testing protocol. Incorporating APOL1 genetic testing into the donor evaluation process is crucial for ensuring donor safety and informed decision-making. Clinicians should also be prepared to provide counselling and support to individuals identified as high-risk, emphasising the importance of regular monitoring and lifestyle interventions to prevent kidney disease.

Conclusion:

The NHS’s introduction of national genetic testing for APOL1 variants represents a significant advancement in personalised medicine and donor care. By identifying high-risk individuals prior to kidney donation, this initiative aims to prevent potential donor complications and address existing health disparities within Black African and Black Caribbean communities. This proactive measure underscores the NHS’s commitment to equitable and safe healthcare practices.

Citation: NHS England. “NHS rolls out national genetic test to reduce risk of donor kidney failure.” 27 January 2025.

Read more: NHS rolls out national genetic test to reduce risk of donor kidney failure